Unraveling Data and Care Strategies for AL Amyloidosis at #ASH24

overview

This 90-minute symposium will feature a panel of hematology/oncology experts who will review the clinical challenges and intricacies of care associated with the management of light chain (AL) amyloidosis. They will provide expert guidance and real-world perspectives related to the complex diagnostic pathway, classification and disease staging, and considerations in treatment selection. Discussion of emerging clinical research will examine concepts driving the field forward to overcome unmet needs. The program will conclude with an interactive Q&A session, allowing attendees to engage directly with the expert panel.

A Friday Satellite Symposium on Hematology, preceding the 66th ASH Annual Meeting and Exposition.

faculty

MODERATOR

Morie A. Gertz, MD, MACP

Roland Seidler Jr. Professor

Department of Medicine

Consultant, Division of Hematology

Mayo Clinic

Rochester, Minnesota

PANELIST

Vaishali Sanchorawala, MD

Professor of Medicine

Director, Amyloidosis Center

Boston Medical Center

Boston University Chobanian & Avedisian School of Medicine

Boston, Massachusetts

PANELIST

Suzanne Lentzsch, MD, PhD

Professor of Medicine

Director, Multiple Myeloma and Amyloidosis Program

Division of Hematology/Oncology

Columbia University Medical Center

New York, New York

AGENDA

11:30 am

Welcome and Introductions: Case Scenario 1

11:35 am

AL Amyloidosis Recognition and Diagnosis

11:50 am

Standards of Care in AL Amyloidosis

12:00 pm

Case Scenario 2

12:05 pm

Challenges in Advanced AL Amyloidosis

12:15 pm

Case Scenario 3

12:20 pm

Addressing Unmet Needs in AL Amyloidosis

12:30 pm

Driving the Field Forward: Emerging Treatment Approaches

12:45 pm

Audience Q&A with Panel Discussion

GOAL STATEMENT

The goal of this activity is for learners to be better able to integrate evidence-based strategies for the optimal multidisciplinary care of patients with AL amyloidosis.

TARGET AUDIENCE

This educational activity is intended for an audience of hematologists/oncologists, cardiologists, primary care physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other members of the multidisciplinary team who treat patients with light chain (AL) amyloidosis in the United States.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: [break] [break] Have increased knowledge regarding the[LIST] [ITEM]Natural history of AL amyloidosis[ITEM]Evolving clinical evidence for AL amyloidosis treatments[/LIST] [break] Have greater competence related to[LIST] [ITEM]Accurately classifying patients with AL amyloidosis [ITEM]Formulating comprehensive care plans for AL amyloidosis[/LIST] [break] Demonstrate greater confidence in their ability to [LIST] [ITEM]Stay abreast of critical evolving evidence that can transform the optimal multidisciplinary care of patients with AL amyloidosis[/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold][break] Medscape, LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [break][break] [bold]For Nurses[/bold][break] Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.00 contact hours are in the area of pharmacology. [break][break] [bold]For Pharmacists[/bold][break]Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-259-L01-P).

Unraveling Data and Care Strategies for AL Amyloidosis CME/CNE/CPE